Unlocking Treatment Success: Overcoming Barriers in Rheumatoid Arthritis Care
"Discover how to navigate patient preferences and disease activity measures for better treatment outcomes in rheumatoid arthritis."
Treat-to-target (TTT) is a strategy for managing rheumatoid arthritis (RA). This approach involves setting clear treatment goals, regularly monitoring disease activity, and making timely adjustments to medication. The aim is to achieve and maintain remission or low disease activity, improving patients' quality of life.
Despite its proven benefits, TTT isn't always implemented. This may stem from clinical inertia, workflow difficulties, or patient-specific situations. Effective TTT implementation requires a deep dive into the reasons behind non-adherence to address gaps and improve care.
A recent study investigated why treatment adjustments aren't made. The goal was to pinpoint the main barriers to TTT adherence. By examining these obstacles, healthcare providers can develop targeted strategies to optimize RA management and improve patient outcomes.
Treat-to-Target in Practice
Treat-to-Target (T2T) in rheumatoid arthritis emphasizes systematic, regular therapy adjustments based on predefined targets, typically remission or low disease activity. Reviews have examined its evidence, practical implementation, effects on comorbidities, and clinical and health-economic impact compared with routine care. A 12-month cluster-randomized trial compared T2T with routine care in adults with active to severely active RA initiating subcutaneous abatacept.
The Development of T2T
Treat-to-target was formally introduced in rheumatology and rheumatoid arthritis in 2010. The T2T algorithm developed that year contained 10 recommendations centered on therapeutic principles, especially targeting remission or low disease activity. Reviews describe T2T and disease-activity measurement as approaches that changed how rheumatologists treat RA, while RA therapies evolved substantially over the preceding 20 years.
Understanding the Roadblocks: Why Treatment Adjustments Stall
The study, a secondary analysis of the TRACTION trial, examined data from patients with RA in an intervention arm. Researchers evaluated medical records to assess TTT implementation, focusing on four key components. Theses were: setting a treatment target, measuring disease activity, shared decision-making, and adjusting treatment when needed.
- Patient Preferences: Many patients were reluctant to change their treatment due to concerns about side effects, costs, or a general resistance to altering their current regimen.
- Disease Activity Discrepancies: Elevated disease activity scores didn't always align with clinical findings. In some cases, patients experienced pain from other conditions, which skewed the scores and made providers hesitant to escalate RA treatment.
- Medication Lag Time: Sometimes, physicians delayed changes due to the time it takes for medications to take full effect.
- Contraindications and Drug Side Effects: Issues such as infection, pregnancy, or side effects also played a significant role in the decision-making process.
Barriers to Treatment Targets
A 2019 review reported that analysis of the TRACTION trial examined barriers to adopting T2T strategies through a randomized controlled study of a Learning Collaborative. Another study found that TTT rates remained low even among patients with moderate to high disease activity attributable to ongoing inflammation when no contraindication to escalation was present. Patient preference has also been identified as one of the leading barriers to treatment adjustment, underscoring the importance of educating patients about T2T.
Contrasting Treatment Reports
One report describes radiosynoviorthese treatment in 260 patients with rheumatoid arthritis. A separate preclinical report evaluated JeEoTang extract in mice with rheumatoid arthritis induced by LPS, administering 3.3 ml/kg/day for 14 days. These reports concern different settings and populations, so their findings should not be treated as a direct comparison of clinical effectiveness.
Enhancing TTT Adherence: A Path Forward
To improve TTT adherence, interventions should focus on using better markers of disease activity, improving alignment with patient preferences. Providers may find adherence to TTT more difficult with certain patients in specific clinical settings. However, our findings from the original trial suggest that TTT adherence can be improved. By addressing these challenges, we can pave the way for more effective RA management and improved patient outcomes.
Emerging Directions in RA Care
Current RA treatment is often holistic, integrating medication, physical therapy, and lifestyle modifications. The main objective is remission or low disease activity through a treat-to-target approach that optimizes drug use and dose adjustments according to clinical response and disease-activity markers. A 2024 overview also emphasizes that pain and stiffness are important contributors to reduced quality of life for patients with rheumatic diseases, including RA and osteoarthritis.
Patient-Centered Care
A real-world study highlights patient-centricity in decision-making as important for defining meaningful treatment targets and selecting appropriate treatments. The study links this approach with efforts to improve disease outcomes. Its reported context includes biological therapy and tumor necrosis factor inhibitors.
T2T Beyond Clinical Trials
The Adelphi RA Disease-Specific Programme used a point-in-time survey of rheumatologists and their consulting patients with RA to investigate T2T implementation across Europe. The study was motivated by limited data on how extensively this endorsed management approach is used in clinical practice. A separate 2026 report describes real-world treatment patterns in Japanese patients with RA, focusing on intensification after methotrexate and prescribing patterns for methotrexate and glucocorticoids within a T2T context.